Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study aims to evaluate the use of circulating tumor DNA (ctDNA) for identifying mutation profiles and monitoring dynamic changes in patients with metastatic colorectal cancer (mCRC) undergoing palliative chemotherapy.
methodsThis prospective observational study enrolled patients with mCRC treated at Asan Medical Center, Korea, between July 2018 and April 2020. ctDNA analysis was performed on plasma samples collected at baseline, first progression (PD), and second PD. Baseline ctDNA profiles were compared with matched tumor NGS data, and longitudinal changes in ctDNA were tracked over time. Clinical outcomes were correlated with ctDNA concentration and variant allele frequency (VAF).
resultsA total of 33 patients were included. ctDNA was detected in 93.9% of patients at baseline. The most frequent mutations were in APC and TP53 (81.8%), followed by KRAS (39.4%) and PIK3CA (30.3%). The median baseline ctDNA VAF was 17.7%, with significantly higher levels observed in patients with liver metastases. The overall concordance rate between plasma and tissue samples was 86.9%, with high accuracy in determining RAS/RAF mutation status. During treatment, acquired mutations emerged; notably, anti-EGFR therapy was associated with new RAS mutations (predominantly Q61 variants), while anti-VEGF therapy induced a broader range of genetic alterations. Elevated baseline ctDNA levels and higher maximum VAF at first PD were significantly correlated with shorter overall survival.
conclusionsctDNA analysis offers a non-invasive approach for comprehensive genomic profiling in mCRC. Its ability to monitor genetic alterations and predict clinical outcomes underscores its potential utility in guiding personalized treatment strategies and monitoring resistance in clinical practice.
Indexed as
Identifiers
41483371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.